Gaetano Chirico
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gaetano Chirico has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
A Gasparoni
1 shared publication- Andrea Dotta
Neonatal Intensive Care Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
1 shared publication - Antonio Boldrini
Santa Chiara University Hospital
1 shared publication - Antonio Del Vecchio
The Italian Pediatric Society, Rome, Italy
1 shared publication C Offer
1 shared publication- Costantino Romagnoli
Division of Neonatology, Department of Pediatrics, Catholic University of the Sacred Heart, Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 15 December 2015
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 41 (1) , 1-8
Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
Respiratory Syncytial Virus infections are one of the leading causes of severe respiratory diseases that require hospitalization and, in some cases, intensive care. Once resolved, there may be respiratory sequelae of varying severity. The lack of effective treatments for bronchiolitis and the lack of vaccines for RSV accentuate the role of prevention in decreasing the impact of this disease. Prevention of bronchiolitis strongly relies on the adoption of environment and the hygienic behavior measures; an additional prophylactic effect may be offered, in selected cases, by Palivizumab, a humanized monoclonal antibody produced by recombinant DNA technology, able to prevent RSV infection by blocking viral replication. After many years the Italian Society of Neonatology, on the basis of the most recent scientific knowledge, has decided to revise recommendations for the use of palivizumab in the prevention of RSV infection.
- 15 December 2015
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 41 (1) , 1-8
Open AccessRevised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
Respiratory Syncytial Virus infections are one of the leading causes of severe respiratory diseases that require hospitalization and, in some cases, intensive care. Once resolved, there may be respiratory sequelae of varying severity. The lack of effective treatments for bronchiolitis and the lack of vaccines for RSV accentuate the role of prevention in decreasing the impact of this disease. Prevention of bronchiolitis strongly relies on the adoption of environment and the hygienic behavior measures; an additional prophylactic effect may be offered, in selected cases, by Palivizumab, a humanized monoclonal antibody produced by recombinant DNA technology, able to prevent RSV infection by blocking viral replication. After many years the Italian Society of Neonatology, on the basis of the most recent scientific knowledge, has decided to revise recommendations for the use of palivizumab in the prevention of RSV infection.
- Open Access
- 1 March 2006
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 91 (2) , F80-F84
A randomised, double blind, placebo controlled trial of the effect of theophylline in prevention of vasomotor nephropathy in very preterm neonates with respiratory distress syndrome
Background: Vasomotor nephropathy is a common renal dysfunction in very preterm neonates. Objective: To determine whether theophylline could prevent vasomotor nephropathy in very preterm infants with respiratory distress syndrome. Methods: A randomised, double blind, placebo controlled trial of 50 preterm infants of gestational age ⩽32 weeks needing assisted ventilation. Infants received an intravenous dose of theophylline (1 mg/kg) or placebo for three days. The 24 hour urine volume was measured daily. On days 2, 5, and 11, blood samples and 12 hour urine collections were analysed for electrolytes, creatinine, and urea. Results: On day 1, urine output was significantly higher in the theophylline (2.4 (0.9) ml/kg/h) than the placebo (1.6 (1.0) ml/kg/h; p = 0.023) group (values are mean (SD)). The incidence of oligoanuria was significantly lower in the theophylline treated (5%) than the placebo (33%) group. Twenty four hours after the first administration of theophylline/placebo, serum creatinine concentration was significantly lower in the theophylline (0.76 (0.23) mg/dl) than the placebo (1.0 (0.41) mg/dl; p = 0.025) group. On day 5 an increase in serum creatinine was observed in both groups. On day 11 a significant reduction in serum creatinine was observed, compared with day 5, with no difference between the two groups. Conclusion: The results suggest that, in very preterm infants with respiratory distress syndrome, early theophylline administration improves renal function during the first two days of life.
- 1 March 2006
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 91 (2) , F80-F84
Open AccessA randomised, double blind, placebo controlled trial of the effect of theophylline in prevention of vasomotor nephropathy in very preterm neonates with respiratory distress syndrome
Background: Vasomotor nephropathy is a common renal dysfunction in very preterm neonates. Objective: To determine whether theophylline could prevent vasomotor nephropathy in very preterm infants with respiratory distress syndrome. Methods: A randomised, double blind, placebo controlled trial of 50 preterm infants of gestational age ⩽32 weeks needing assisted ventilation. Infants received an intravenous dose of theophylline (1 mg/kg) or placebo for three days. The 24 hour urine volume was measured daily. On days 2, 5, and 11, blood samples and 12 hour urine collections were analysed for electrolytes, creatinine, and urea. Results: On day 1, urine output was significantly higher in the theophylline (2.4 (0.9) ml/kg/h) than the placebo (1.6 (1.0) ml/kg/h; p = 0.023) group (values are mean (SD)). The incidence of oligoanuria was significantly lower in the theophylline treated (5%) than the placebo (33%) group. Twenty four hours after the first administration of theophylline/placebo, serum creatinine concentration was significantly lower in the theophylline (0.76 (0.23) mg/dl) than the placebo (1.0 (0.41) mg/dl; p = 0.025) group. On day 5 an increase in serum creatinine was observed in both groups. On day 11 a significant reduction in serum creatinine was observed, compared with day 5, with no difference between the two groups. Conclusion: The results suggest that, in very preterm infants with respiratory distress syndrome, early theophylline administration improves renal function during the first two days of life.